Condition: Smoldering Plasma Cell Myeloma · Sponsor: ECOG-ACRIN Cancer Research Group
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Recruiting |
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | Recruiting |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | Suspended |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | Recruiting |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | Recruiting |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | Recruiting |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | Suspended |
| Katmai Oncology Group | Anchorage, Alaska, United States | Recruiting |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | Recruiting |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | Recruiting |
| CTCA at Western Regional Medical Center | Goodyear, Arizona, United States | Recruiting |
| Kingman Regional Medical Center | Kingman, Arizona, United States | Recruiting |
+ 735 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03937635